Zora Biosciences is a diagnostics company. We identify robust markers of disease and develop them into high-throughput, health-economic value-added clinical methods.

We are passionate in finding and developing new diagnostics in order to improve health, increase quality of life and healthy years, and lower healthcare costs.

We use our existing mass spectrometry platforms, our extensive collaborator network for clinical studies, and in-licensing capabilities to generate biomarker candidates. Appropriate studies using well characterized and sizeable sample sets are employed for series of validation runs. Extensive patenting is sought for all discovery IP through our expert partner patent offices.

The central commercialization pathway in the United States is the licensing of Zora IP to reference laboratories that develop LDTs (Laboratory Developed Test) under CLIA regulation. Potential multi-national kit approaches for the diagnostic products are also possible.

 

Management

Reini Hurme, PhD, eMBA

CEO, Co-founder

Reini worked in pharmaceutical industry for 8 years, managing various clinical departments and functions for Leiras Oy and Schering Oy global organizations. He has worked in academia in the field of biochemistry and molecular biology with notable awards, grants, and publications, conducting research at Institut Pasteur, Karolinska Institute, and University of Helsinki. Reini has spent about twenty years abroad both in the US and several European countries. At Zora Reini has attracted funding and steered the business for growing the company from a start-up to a more mature company with marketed products and a strong diagnostic pipeline.

Reijo Laaksonen, Prof, MD, FESC

CMO, Co-founder

Reijo is a clinical pharmacologist specialized in cardiovascular pharmacology. Reijo spent more than six years at the Clinical Research Institute of Montreal and at the Laboratory of Experimental Neurology, ULB, Brussels as a post-doctoral fellow and visiting scientist. Prior to joining Zora Reijo has worked as Chief Research Scientist at Viikki Drug Discovery Technology Center, Helsinki and served as a consultant for pharmaceutical and biotechnology companies. Reijo is co-inventor of several patents and has published over 100 original scientific articles. Reijo is also research professor at Tampere University and medical director of the Finnish Clinical Biobank Tampere. Reijo’s interest in cardiovascular disease prevention and his experience in statin intolerance work are key assets for the development of the Zora porfolio.

Riikka Katainen, MSc (Econ, Biotech)

COO

Riikka holds an M.Sc. in Business and Economics as well as M.Sc. in Biotechnology. She worked at the University of Helsinki as a researcher. Prior to joining Zora, Riikka worked at Thermo Fisher Scientific. During her career she has gained invaluable experience in IPR, especially in patenting. Additionally, she has experience in project management, management accounting, financial management, and management of publicly funded projects. At Zora Riikka has been instrumental in creating project management practices, developing the patenting strategy, and managing our publicly funded projects and in building the company brand and marketing strategy.

Mika Hilvo, PhD, Adj. Prof.

Head of Bioinformatics

Mika Hilvo holds a PhD in Medical Technology and Biotechnology from University of Tampere, Finland. After completing his PhD, Mika worked for more than 5 years for VTT Technical Research Centre of Finland, where his main task was to lead cancer-related metabolomic and lipidomic study projects. Mika spent year 2013 as a visiting scientist in Cambridge, UK, as part of his 3-year project funded by the Academy of Finland. In addition to his expertise in oncology, Mika’s talent in combining biology and bioinformatics is a strength for our discovery and development work.

Dimple Kauhanen, MSc

Head of Biomarker Discovery and Analytical Quality

Dimple Kauhanen has over 15 years’ experience working with mass spectrometry and analytical validation. She has pharmaceutical industry experience from GlaxoSmithKline, United Kingdom, where she spent over five years in DMPK successfully developing and validating various drug assays in GLP environments. Before that she held a position in the food and feed testing unit at Eurofins Scientific. During her career she has gained invaluable knowledge in lipid research, analytical services, biomarker development and in addition has had the opportunity to collaborate with numerous research organizations and pharmaceutical companies. At Zora Dimple has generated and validated assays needed for our diagnostic products.

Virve Väisänen, MSc

Head of Intellectual Property Rights

Virve Väisänen manages Zora’s diagnostic patent portfolio and other IPR. Virve holds an MSc in analytical chemistry from the University of Helsinki. She has experience in IPR and quality management in the chemical industry and also in analytical laboratories. At Zora Virve has handled scores of patent application in various geographies, with several of these coming to fruition thereby strengthening the Zora portfolio.

Board

Aleksander Golob

Chairman of the Board, President of the Board of GOMAR d.d.

Aleksander Golob is the President of the Board, founder, and major shareholder of GOMAR d.d., a Slovenian private consulting enterprise. Aleksander is an engineer by training and also holds an MBA from the University of Maribor. His financial expertise was acquired during a banking career in a prominent investment bank in Slovenia. Aleksander is specialized in financial and tax consultation.

Simo Makkonen

Chairman of the Board of Circlion Capital Oy, Dr.Tech

Simo Makkonen is the Chairman of the Board and founder of Circlion Capital Oy, a Finnish private investment company. Simo was the CEO, founder, and key shareholder of Process Vision Oy, a mid-size IT company specialized in energy management systems. Simo has 20 years of experience in energy, IT and management. After Process Vision sell-off in 2011, Simo has been involved in senior advisory and consulting activities in addition to his role as an investor in several European companies. His academic career has focused on applied mathematics, operations research, international financing and artificial intelligence.

Timo Laitinen

M.Sc. (Eng)

Heinz Drexel

Prof.

Department of Internal Medicine and Cardiology, State Hospital Feldkirch

Partners

Charité – Universitätsmedizin Berlin

Prof. Dr. Ulf Landmesser, Chairman Department of Cardiology, BIH Professor of Cardiology

University of Bergen

Prof. Rolf Kristian Berge, Klinisk Institutt 2

University of Milan

Giulia Chiesa, Assistant Professor, Department of Pharmacological Sciences, Faculty of Pharmacy

HUS / HYKS Sydän- ja keuhkokeskus

Juha Sinisalo, Osastonylilääkäri, Kardiologia

RiskyCAD

Zora is a partner in RiskyCAD Project funded by European Commission Seventh Framework Programme

AtheroFLUX

Zora is a partner in AtheroFLUX Project funded by European Commission Seventh Framework Programme